Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Use of a metabolomic approach to non-invasively diagnose non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
复制标题
DOI：
10.1111/dom.13285
复制
发表时间：
2018-07-01
影响因子：
5.8
通讯作者：
Cusi, Kenneth
中科院分区：
文献类型：
--
作者：
Bril, Fernando;Millan, Laura;Cusi, Kenneth
目的：评估现有代谢组学评分对 2 型糖尿病 (T2DM) 患者肝病分类的效用。材料和方法：总共招募了 220 名 T2DM 患者。患者接受常规实验室检查、肝脏质子磁共振波谱 (H-1-MRS)、75 g 口服葡萄糖耐量试验，如果 H-1-MRS 结果表明非酒精性脂肪肝，则进行肝活检。盲目地向 OWL Metabolomics 提供血清样本，用于运行 OWLiver Care 和 OWLiver 测试。结果：与肝活检相比，OWLiver Care 和 OWLiver 测试在 T2DM 患者中的表现欠佳（接受者操作特征 [AUROC] 曲线下的面积均
Aims: To assess the utility of existing metabolomics scores to classify liver disease in patients with type 2 diabetes mellitus (T2DM).Materials and methods: A total of 220 patients with T2DM were recruited. Patients underwent routine laboratory tests, liver proton magnetic resonance spectroscopy (H-1-MRS), a 75-g oral glucose tolerance test, and liver biopsy if H-1-MRS findings indicated non-alcoholic fatty liver disease. A serum sample was blindly provided to OWL Metabolomics on which to run the OWLiver Care and OWLiver tests.Results: When compared with liver biopsy, the OWLiver Care and OWLiver tests had a suboptimal performance in patients with T2DM (areas under the receiver-operating characteristic [AUROC] curve both